(NASDAQ: RPRX) Royalty Pharma's forecast annual revenue growth rate of 14.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.11%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.17%.
Royalty Pharma's revenue in 2024 is $2,238,561,000.On average, 2 Wall Street analysts forecast RPRX's revenue for 2024 to be $1,595,155,721,258, with the lowest RPRX revenue forecast at $1,594,102,439,349, and the highest RPRX revenue forecast at $1,596,209,003,167. On average, 2 Wall Street analysts forecast RPRX's revenue for 2025 to be $1,739,525,242,921, with the lowest RPRX revenue forecast at $1,699,942,036,531, and the highest RPRX revenue forecast at $1,779,108,449,311.
In 2026, RPRX is forecast to generate $1,889,911,555,340 in revenue, with the lowest revenue forecast at $1,855,705,881,826 and the highest revenue forecast at $1,924,117,826,291.